Number To Know…1,000

1,000 is the target number of patients Vigilant Biosciences is looking to recruit for the clinical study of its OncAlert oral cancer risk assessment point-of-care test. The study is designed to validate performance and evaluate implementation of the assay as a first-in-line screening test for patients with increased clinical risk for oral/oropharyngeal cancer. The study will enroll patients in the US as well as internationally and the data will be used for the company's US FDA approval application.

Meddevicetracker subscribers can access a full analysis of Vigilant Bioscience's product portfolio, including the clinical and regulatory status of the...